Unicycive Therapeutics to Participate in Upcoming Investor Events in September
Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease treatments, has announced its participation in two upcoming investor events in September 2025.
CEO Shalabh Gupta will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 8:30 a.m. ET, followed by another fireside chat at the Truist Securities Virtual event on September 17 at 10 a.m. ET. Webcasts will be available on the company's investor relations website.
Unicycive Therapeutics (Nasdaq: UNCY), societ脿 biotech in fase clinica focalizzata sui trattamenti per le malattie renali, ha annunciato la sua partecipazione a due eventi per investitori previsti per settembre 2025.
Il CEO Shalabh Gupta prender脿 parte a una conversazione informale al H.C. Wainwright 27th Annual Global Investment Conference il 10 settembre alle 8:30 ET, e a un secondo intervento in formato fireside all'evento virtuale Truist Securities il 17 settembre alle 10:00 ET. I webcast saranno disponibili sul sito web delle relazioni con gli investitori della societ脿.
Unicycive Therapeutics (Nasdaq: UNCY), una empresa biotecnol贸gica en fase cl铆nica centrada en tratamientos para enfermedades renales, ha anunciado su participaci贸n en dos eventos para inversores en septiembre de 2025.
El CEO Shalabh Gupta participar谩 en una charla informal en la H.C. Wainwright 27th Annual Global Investment Conference el 10 de septiembre a las 8:30 a.m. ET, y en otra charla informal en el evento virtual de Truist Securities el 17 de septiembre a las 10:00 a.m. ET. Los webcast estar谩n disponibles en la web de relaciones con inversores de la compa帽铆a.
Unicycive Therapeutics (Nasdaq: UNCY), 鞁犾灔 歆堩櫂 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓ろ厤 旮办梾鞚� 2025雲� 9鞗� 臧滌禍霅橂姅 霊� 彀鞚� 韴瀽鞛� 頄夓偓 彀戈皜毳� 氚滍憸頄堨姷雼堧嫟.
CEO 靸澕敫� 甑巾儉(Shalabh Gupta)電� 9鞗� 10鞚� 鞓れ爠 8:30(ET)鞐� 鞐措Μ電� H.C. Wainwright 27th Annual Global Investment Conference鞐愳劀 韺岇澊鞏挫偓鞚措摐 韱犿伂(雽�雼�)鞐� 彀戈皜頃橁碃, 9鞗� 17鞚� 鞓れ爠 10:00(ET)鞐� 鞐措Μ電� Truist Securities鞚� 臧�靸� 頄夓偓鞐愳劀霃� 霕� 雼るジ 雽�雼挫棎 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 鞗轨簮鞀ろ姼電� 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 鞁滌箔頃橃嫟 靾� 鞛堨姷雼堧嫟.
Unicycive Therapeutics (Nasdaq: UNCY), une biotech en phase clinique ax茅e sur les traitements des maladies r茅nales, a annonc茅 sa participation 脿 deux 茅v茅nements investisseurs en septembre 2025.
Le PDG Shalabh Gupta participera 脿 une discussion informelle lors de la H.C. Wainwright 27th Annual Global Investment Conference le 10 septembre 脿 8h30 ET, puis 脿 un second entretien informel 脿 l'茅v茅nement virtuel de Truist Securities le 17 septembre 脿 10h00 ET. Les webcasts seront disponibles sur le site relations investisseurs de la soci茅t茅.
Unicycive Therapeutics (Nasdaq: UNCY), ein klinisch fortgeschrittenes Biotech-Unternehmen mit Schwerpunkt auf Nierenerkrankungen, hat seine Teilnahme an zwei Investorenveranstaltungen im September 2025 angek眉ndigt.
CEO Shalabh Gupta wird am 10. September um 8:30 Uhr ET an einem Fireside-Chat auf der H.C. Wainwright 27th Annual Global Investment Conference teilnehmen und am 17. September um 10:00 Uhr ET an einem weiteren Fireside-Chat beim virtuellen Event von Truist Securities. Webcasts stehen auf der Investor-Relations-Website des Unternehmens zur Verf眉gung.
- None.
- None.
LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.聽(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the 鈥淐ompany鈥� or 鈥淯nicycive鈥�), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two investor events in September.
Event: H.C. Wainwright 27th Annual Global Investment Conference
Type: Fireside chat
Date/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET
Event: Truist Securities Virtual Fireside Chat
Date/Time: Wednesday, September 17, 2025, at 10 a.m. ET
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: . To schedule a 1x1 meeting with management, please contact your conference representative.
About聽Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive鈥檚 lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive鈥檚 second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit聽聽and follow us on聽听补苍诲听.
Investor Contact:
Kevin Gardner
LifeSci Advisors
Media Contact:
Rachel Visi
AG真人官方 Chemistry
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When is Unicycive Therapeutics (UNCY) presenting at the H.C. Wainwright Conference?
What type of events will Unicycive (UNCY) participate in during September 2025?
How can investors access Unicycive's (UNCY) September 2025 presentations?
What is Unicycive Therapeutics' (UNCY) main focus area?
